AUTHOR=Lv Yufan , Luo Xinyu , Xie Zhuoyi , Qiu Jieya , Yang Jinsai , Deng Yuqi , Long Rou , Tang Guiyang , Zhang Chaohui , Zuo Jianhong 

TITLE=Prospects and challenges of CAR-T cell therapy combined with ICIs

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1368732

DOI=10.3389/fonc.2024.1368732

ISSN=2234-943X

ABSTRACT=<p>Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.</p>